Oncocyte (NASDAQ:IMDX) executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial launch and managing spending ahead of expected revenue growth.
During the company’s second-quarter call
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Insight Molecular Dx (IMDX) stock fell 11.8% after missing Q3 2025 revenue and EPS estimates. The company remains focused on its FDA submission for the GraftAssureDx™ test.
